Patient reported outcomes between clinic visits: worth doing? RA pts starting ADA/UPA, n=150 ArthritisPower/PatientSpot app for PROs between visits 52% of CDAI change explained by PROs Maybe a helpful tool in prioritising RA clinic reviews? @RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ Pos#L10 https://t.co/DfChrAyslL

PEXIVAS results: the reduced-dose GC regimen associated w/ ^ death, ESRD, and uncontrolled dz risk in severe GPA/MPA pts. Even greater risk in pts w/ creatinine levels > 300 μmol/L & in those tx w/ RTX induction. #ACR23 Plenary 0725 https://t.co/mBMrEaGj5k @rheumnow https://t.co/flAfYEKSXJ

DESIR cohort update in Abs #0513 shows axSpA pt imaging doesn't "worsen" after pregnancy. However, following 1st pregnancy, can see slight increase in L SIJ score, but typically not enough to define "worsening." #ACR23 https://t.co/HaYj3RQGFb @rheumnow https://t.co/5MQCXS1Kat

Acute pregnancy-related CV event risk found to be highest in pts w/ SLE+ APS, followed by primary APS, and SLE w/ LN. Most importantly, 25-30% of events happen post-partum! Monitor these pts carefully! #ACR23 Plenary 0722 #ACRbest https://t.co/yD5VFJ2SXh @rheumnow https://t.co/PDvzbs19fR

Prof Mustelin explains why Basic Science research is important in medicine. New ideas need: 👉discovery 👉explanation 👉 impact #ACR23 @rheumnow #YearInReview #BasicScience https://t.co/t0W3GdUtWD

Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt

Dr. Seo shares an interesting case report on the use of anti-TRBV9 Ab in a patient with AS. Another potential treatment option for AS?🧐 Something to watch out for in the future. #ACR23 @RheumNow @rheumarhyme https://t.co/y6mQ756TKK

A new way to die! #Ferroptosis may be a more important means of cell death. It’s an intracellular iron-dependent form of cell death that is distinct from apoptosis, necrosis, and autophagy #ACR23 @rheumnow #YearInReview https://t.co/DB7iuwuWTX https://t.co/v5Z2Od8mJ7

Q&A from RA-ILD Guidelines Presentation: Q: "Why was AZA recommended but ABA was not?" A: "The evidence was not as good for it so it was not included" Can anyone explain this to me? Where is this amazing data for AZA in RA-ILD? @RheumNow #ACR23

#ACR23 Year in Review. CAR-T cell showed promising results in #SLE based on case series but extrapolation to other RMD may be challenging. -Myositis recurred after 7days, needing MMF -No improvement in lung fibrosis #SSc Longer-term data & trial data are needed @RheumNow https://t.co/4Zmjvr51Ab

More good data for benralizumab (IL5i) in EGPA, @TerrierBen There may be additional benefit over MEPO given deeper eosinophil depletion Checkout our recent editorial about this in @TheLancetRheum @RheumNow #ACR23 https://t.co/1d2nITOuOs

Our work showed the PSAID-12 score done remotely correlated with in-person clinic assessment of tender (r=0.58) , swollen joint count (r= 0.51), pain (r=0.84). 21% of patients had low disease activity onPSAID12 assessment, Chan A #Abst0507 #ACR23 @RheumNow https://t.co/vorth2ko39 https://t.co/Q2Y3ApD47E

Why do we do translational research? Dr Mustelin outlines different goals of basic science in #yearinreview I would emphasize the #1: understanding pathogenesis is key to address clinical challenges Overall “we have much more work to do than we care to admit” @RheumNow #ACR23 https://t.co/QtBO3Go3gD